Rango de valoración compuesto · conservador ¥2,450–¥2,650 / razonable ¥3,250–¥4,150 / optimista ¥5,150–¥5,450. A ¥3,436, Dentro del rango de valor intrínseco razonable.
Fujifilm and HORIBA co-developed an inline Raman monitoring system for biopharma manufacturing, citing about 10% antibody-yield improvement.
Possible impact:May affect expectations for Bio-CDMO process efficiency, cost control, and technology differentiation.
FUJIFILM Cellular Dynamics opened a Madison iPSC development and manufacturing facility, part of a $200 million U.S. expansion.
Possible impact:May affect expectations for life-science and cell-therapy manufacturing capacity and long-term growth.
Fujifilm reported record fiscal-year revenue, with Imaging revenue up 15.7%, while warning of memory and silver cost pressure.
Possible impact:May affect expectations for Imaging growth durability and the group’s ability to offset input-cost inflation.
Fujifilm reported FY2026 revenue up 5.0% and operating income up 6.1%, with FY2027 guidance for further growth.
Possible impact:May affect expectations for earnings resilience and growth in imaging and semiconductor materials.
FY2026 revenue rose 5.0% to JPY3.357 trillion and operating income rose 6.1%; Fujifilm guided for record FY2027 performance.
Possible impact:May affect expectations for continued growth in healthcare, electronic materials, and imaging.
Automatically summarized from public sources; for context only, not investment advice.
Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.
FUJIFILM Holdings Corporation provides products and services in the fields of healthcare, electronics, business innovation, and imaging in Japan, the Americas, Europe, Asia, and internationally. The Healthcare segment offers products and services, such as medical devices, biomedical contract development and manufacturing organization, pharmaceutical, regenerative medicine, and cosmetics and supplements in the areas of prevention, diagnosis, and treatment; equipment and materials for medical systems; drug discovery support, such as iPS cells; and cell culture media and reagents. Its Electronic segment provides display and touch panel, semiconductor and image sensors, and functional film materials; storage media and archiving services; semiconductor and display materials; industrial equipment; and fine chemicals. The Business Innovation segment offers office equipment, including multi-function devices and printers; problem-solving document services tailored to diverse business formats and roles, including system integration, cloud service, business process outsourcing, and others; equipment and materials for graphic communications; and inks and industrial inkjet printheads. Its Imaging segment provides color films, instant cameras, developing and printing systems, color papers, and photo printing services; TV and cinema lenses, surveillance cameras, industrial lenses for production line inspection, and projectors; instant photo systems; services for photofinishing; digital cameras; and optical devices. FUJIFILM Holdings Corporation was incorporated in 1934 and is headquartered in Minato, Japan.
PróximamenteEsta sección se está completando; vuelve pronto.
PróximamenteEsta sección se está completando; vuelve pronto.
Aún no hay análisis sobre este valor en tu idioma.
